Jack Boyle Net Worth

The estimated Net Worth of Jack D. Boyle is at least $18.6 ezer dollars as of 2 April 2021. Mr. Boyle owns over 22,962 units of Endo International plc stock worth over $18,608 and over the last 5 years he sold ENDP stock worth over $0. In addition, he makes $0 as Senior Vice President - Financial Planning & Analysis, Chief Accounting Officer és Controller at Endo International plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Boyle ENDP stock SEC Form 4 insiders trading

Jack has made over 2 trades of the Endo International plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 22,962 units of ENDP stock worth $6,719 on 2 April 2021.

The largest trade he's ever made was exercising 22,962 units of Endo International plc stock on 2 April 2021 worth over $6,719. On average, Jack trades about 4,478 units every 58 days since 2020. As of 2 April 2021 he still owns at least 63,595 units of Endo International plc stock.

You can see the complete history of Mr. Boyle stock trades at the bottom of the page.

Jack Boyle biography

Jack D. Boyle serves as Senior Vice President - Financial Planning & Analysis, Chief Accounting Officer, Controller of the Company. Mr. Boyle joined Endo in 2007 as Financial Reporting Manager and assumed various roles of increasing responsibility, most recently serving as Senior Vice President, Financial Planning and Analysis since February 2018. Previously, he served as Vice President, Finance - Branded Pharmaceuticals from November 2016 until February 2018; Vice President, Finance for Endo’s International Unit from August 2014 until November 2016; Senior Director, FP&A from March 2011 until August 2014; and Director, Internal Audit from January 2008 until March 2011. Prior to joining Endo, Mr. Boyle served as a public accountant for Ernst & Young LLP from 1997 until 2007. Mr. Boyle is a licensed certified public accountant in the Commonwealth of Pennsylvania, and holds a Bachelor of Science degree in accounting from Bucknell University and an MBA from the Leonard N. Stern School of Business at New York University.

How old is Jack Boyle?

Jack Boyle is 44, he's been the Senior Vice President - Financial Planning & Analysis, Chief Accounting Officer és Controller of Endo International plc since 2020. There are 16 older and no younger executives at Endo International plc. The oldest executive at Endo International plc is Michael Hyatt, 74, who is the Independent Director.

What's Jack Boyle's mailing address?

Jack's mailing address filed with the SEC is C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN, L2, .

Insiders trading at Endo International plc

Over the last 11 years, insiders at Endo International plc have traded over $3,455,441 worth of Endo International plc stock and bought 152,347 units worth $3,901,804 . The most active insiders traders include Silva Rajiv De, Paul Campanelli és Shane Cooke. On average, Endo International plc executives and independent directors trade stock every 36 days with the average trade being worth of $12,163. The most recent stock trade was executed by Patrick A Barry on 29 March 2022, trading 59,298 units of ENDP stock currently worth $17,351.

What does Endo International plc do?

Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them.

Complete history of Mr. Boyle stock trades at Endo International plc

Endo International plc executives and stock owners

Endo International plc executives and other stock owners filed with the SEC include:

• Paul Campanelli,
  Chairman of the Board
• Terrance Coughlin,
  Chief Operating Officer, Executive Vice President
• Blaise Coleman,
  Pres, CEO & Director
• Blaise Coleman,
  President, Chief Executive Officer, Director
• Matthew Maletta,
  Executive Vice President, Chief Legal Officer
• Patrick Barry,
  Executive Vice President and Chief Commercial Officer, U.S. Branded Business
• Patrick A. Barry,
  Exec. VP & Pres of Global Commercial Operations
• Mark T. Bradley,
  Exec. VP & CFO
• Roger Kimmel,
  Senior Independent Director
• Shane Cooke,
  Independent Director
• William Montague,
  Independent Director
• Nancy Hutson,
  Independent Director
• Michael Hyatt,
  Independent Director
• M. Christine Smith,
  Independent Director
• Mark Barberio,
  Independent Director
• Jack Boyle,
  Senior Vice President - Financial Planning & Analysis, Chief Accounting Officer, Controller
• Rahul Garella,
  Executive Vice President, International Pharmaceuticals
• Domenico Ciarico,
  Executive Vice President and Chief Commercial Officer, Sterile and Generics
• Joseph A. Barbarite,
  Exec. VP of Global Quality and Compliance
• Tracy Basso,
  Chief HR Officer
• Susan Williamson,
  Sr. VP & Chief Compliance Officer
• Laure E. Park,
  Sr. VP of Investor Relations & Corp. Affairs
• Ruth Thorpe,
  Sr. VP of Information Technology & Chief Information Officer
• Robert Polke,
  Exec. VP & Global Head of Operations
• Arthur J Higgins,
  Director
• Douglas S Ingram,
  Director
• Hemanth Jacob Varghese,
  Pres. International Pharma
• Suketu Upadhyay,
  EVP, Chief Financial Officer
• Antonio R Pera,
  President, Par Pharmaceutical
• Joseph Ciaffoni,
  President, U.S. Branded Pharma
• Carrie Ann Nichol,
  SVP, Controller & CAO
• Mark T. Bradley,
  EVP, Chief Financial Officer
• Frank B. Raciti,
  VP, Controller and CAO
• Daniel Rudio,
  Vice President, Controller
• Sharad Mansukani,
  Director
• William Spengler,
  Director
• Silva Rajiv De,
  President & CEO
• John Delucca,
  Director
• Brian Lortie,
  President Branded Pharma
• Susan Hall,
  EVP, CSO, Global Head of R&D
• Caroline B Manogue,
  Exec. V.P., CLO & Secy
• Camille Farhat,
  President, AMS, Inc.
• Ivan P. Gergel,
  EVP, R&D and CSO
• Donald W De Golyer,
  Chief Operating Officer,Pharma
• Mary Christine Smith,
  Director
• George Apostol,
  EVP, Global R&D
• Jennifer M Chao,
  Director
• James Patrick Tursi,
  Executive VP, Global R&D